ProMIS Q3 net loss $2.4M, cash $16.9M; starts Phase 1a PMN310 Alzheimer's trial

ProMIS Neurosciences Inc.

2023-Q3 EPS reported -$0.98

Net loss $2.4M in Q3 2023 vs $6.0M in Q3 2022; R&D expenses dropped to $1.1M from $4.6M.
Cash $16.9M at Sep 30, 2023, up from $5.9M at Dec 31, 2022, after $20.4M gross PIPE proceeds.
Phase 1a trial of PMN310 for Alzheimer's: first subjects dosing expected Nov 2023; early cohort results in H1 2024.
Raised $20.4M via private placement of ~10M shares and ~955K pre-funded warrants in August 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

ProMIS Neurosciences Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was $2.4 million for the quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Net income: Net loss was $2.4 million for the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

ProMIS Neurosciences Inc. (the "Company") issued a press release, which is available on its website (www.promisneurosciences.com under “Investors/Financial Results”), reporting its financial condition and financial results as of and for the three and nine months ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

ProMIS Neurosciences Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-019067

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.